BNP (B-type Natriuretic Peptide) vs Sermorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
BNP (B-type Natriuretic Peptide)
BNP is a cardiac neurohormone released primarily by ventricles in response to volume/pressure overload. It's a major biomarker for heart failure and has therapeutic applications as nesiritide.
Full details →Sermorelin
Sermorelin is a synthetic analog of GHRH consisting of the first 29 amino acids of the natural hormone. It was previously FDA-approved for GH deficiency diagnosis and treatment in children.
Full details →Side-by-Side Comparison
| Aspect | BNP (B-type Natriuretic Peptide) | Sermorelin |
|---|---|---|
| Dose Range | 25 mcg–100 mcg | 100 mcg–300 mcg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 1–4 weeks | 8–12 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Similar to ANP - activates NPR-A receptors to produce vasodilation, natriuresis, and RAAS suppression. Released in response to ventricular wall stress. | Binds to GHRH receptors in the pituitary gland to stimulate natural GH production and release. Maintains the body's natural feedback mechanisms for GH regulation. |
| Typical Dosage | Nesiritide (recombinant BNP): 2mcg/kg IV bolus followed by 0.01mcg/kg/min continuous infusion for acute decompensated heart failure. | Typical dosing: 200-500mcg administered once daily, usually before bed. Some protocols use twice daily dosing. |
| Administration | Intravenous administration only. Used in acute care settings for heart failure. BNP levels also used diagnostically. | Subcutaneous injection, preferably at bedtime to work with natural GH release patterns. Can be combined with GHRPs for synergistic effects. |
| Side Effects | Hypotension (common and dose-limiting), headache, nausea, and potential renal function worsening in some patients. | Generally well-tolerated. May cause injection site reactions, headache, flushing, or dizziness. Less side effects than direct GH administration. |
| Best For |
What They Have in Common
BNP (B-type Natriuretic Peptide), Sermorelin are both commonly used for:
Key Differences
Unique to Sermorelin:
Which Has Stronger Evidence?
| Goal | BNP (B-type Natriuretic Peptide) | Sermorelin |
|---|---|---|
| Recovery & Healing | medium | medium |
Key Studies
BNP (B-type Natriuretic Peptide)
- Developing a risk score for B-type natriuretic peptide (BNP) ≥ 100 pg/ml levels: the suita study.
BMC cardiovascular disorders, 2025
- Inhibition of Fap Promotes Cardiac Repair by Stabilizing BNP.
Circulation research, 2023
- Body Composition Measures and N-terminal pro-B-type Natriuretic Peptide (NT-pro-BNP) in US Adults.
Clinical chemistry, 2023
Sermorelin
- A potentially effective drug for patients with recurrent glioma: sermorelin.
Annals of translational medicine, 2021
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Clinical interventions in aging, 2006
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 1999
Ready to Learn More?
Looking for trusted sources?